Skip to main content
. Author manuscript; available in PMC: 2014 May 27.
Published in final edited form as: Curr Pharm Des. 2013;19(18):3215–3225. doi: 10.2174/13816128113199990300

Fig. (6). MLN4924, an inhibitor of NEDD8-activating enzyme for cancer therapy.

Fig. (6)

(A) Chemical structure of MLN4924. (B) MLN4924 blocks neddylation of all cullins tested and cause the accumulation of CRL substrates. MCF7 cells were treated with 1.0 μM MLN4924 or DMSO vehicle control for indicated time periods, followed by Western blotting with indicated antibodies. (C) MLN4924 induces apoptosis. MCF7 cells were treated with 1.0 μM MLN4924 for indicated time periods, followed by Western blotting with indicated antibodies. (D) MLN4924 induces autophagy. HeLa cells stably expressing EGFP-LC3 were treated with 1.0 μM MLN4924 or DMSO control for 24 h prior to photography under a fluorescent microscope. (E) A model for suppression of cancer cell growth by MLN4924.